Koninklijke DSM N.V. (KDSKF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Koninklijke DSM N.V. (KDSKF) with AI Score 41/100 (Weak). Koninklijke DSM N. V. is a global science-based company operating in nutrition, health, and sustainable living. Market cap: 0, Sector: Basic materials.
Last analyzed: Mar 16, 2026Koninklijke DSM N.V. (KDSKF) Materials & Commodity Exposure
Koninklijke DSM N.V. operates as a global science-based company, delivering nutrition, health, and sustainable living solutions. With a diverse portfolio spanning nutrition, materials, and biomedical innovations, DSM serves industries worldwide, leveraging its scientific expertise to address evolving market needs and sustainability challenges, while facing competition from peers like BOALF and BOALY.
Investment Thesis
Koninklijke DSM N.V. presents an investment case predicated on its diversified business model and strategic positioning in growing markets. The company's focus on nutrition, health, and sustainable living aligns with increasing consumer demand for healthier and more sustainable products. DSM's innovation pipeline, particularly within its Innovation Center segment, offers potential for long-term growth. However, the company's P/E ratio of 41.69 suggests a premium valuation, requiring careful consideration of future earnings growth. The dividend yield of 0.82% provides a modest income stream. Investors should monitor the company's ability to maintain its profit margin of 5.7% and effectively manage its beta of 0.72 in a dynamic market environment. The company's gross margin stands at 32.1%.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $4.40B reflects its substantial presence in the specialty chemicals and life sciences sectors.
- P/E ratio of 41.69 indicates a premium valuation compared to the industry average, suggesting high investor expectations.
- Profit Margin of 5.7% demonstrates the company's ability to generate profits from its revenue, but it is lower than some competitors.
- Gross Margin of 32.1% reflects the efficiency of its production and pricing strategies.
- Dividend Yield of 0.82% provides a modest income stream for investors.
Competitors & Peers
Strengths
- Diversified business model across nutrition, materials, and biomedical segments.
- Strong focus on innovation and sustainability.
- Established market presence and brand reputation.
- Extensive portfolio of proprietary technologies.
Weaknesses
- Relatively low profit margin compared to some competitors.
- High P/E ratio suggesting a premium valuation.
- Exposure to fluctuations in raw material prices.
- Dependence on research and development for future growth.
Catalysts
- Ongoing: Expansion of personalized nutrition offerings to drive revenue growth.
- Ongoing: Development of sustainable materials to meet increasing demand for eco-friendly products.
- Ongoing: Advancements in biomedical materials for medical devices and implants.
- Upcoming: Potential strategic partnerships and acquisitions to expand market reach by Q4 2026.
- Upcoming: Implementation of digital technologies and data analytics to improve operational efficiency by Q2 2027.
Risks
- Potential: Intense competition from other specialty chemical and life science companies.
- Potential: Regulatory changes and environmental concerns impacting operations.
- Potential: Economic downturns and market volatility affecting demand for products.
- Ongoing: Fluctuations in raw material prices impacting profitability.
- Ongoing: Dependence on research and development for future growth.
Growth Opportunities
- Expansion in Personalized Nutrition: The growing trend of personalized nutrition presents a significant opportunity for DSM. By leveraging its expertise in vitamins, minerals, and nutraceuticals, DSM can develop customized solutions tailored to individual needs. The personalized nutrition market is projected to reach $16.9 billion by 2025, offering substantial growth potential for DSM. This involves creating tailored supplements and dietary plans based on individual genetic profiles and lifestyle factors, enhancing customer loyalty and driving revenue growth.
- Sustainable Materials Innovation: DSM's Materials segment can capitalize on the increasing demand for sustainable plastics and bio-based materials. By investing in research and development, DSM can create innovative solutions that reduce environmental impact and meet the needs of eco-conscious consumers. The sustainable materials market is expected to grow at a CAGR of 8.7% from 2021 to 2028, driven by stricter regulations and growing consumer awareness. DSM's Dyneema fiber solution can be further developed for renewable energy applications.
- Biomedical Materials Advancements: The Innovation Center segment can drive growth by developing advanced biomedical materials for medical devices and implants. With an aging global population and increasing demand for minimally invasive procedures, the market for biomedical materials is expected to grow significantly. DSM can focus on areas such as cardiovascular, orthopedic, and wound management to develop innovative solutions that improve patient outcomes and drive revenue growth. This includes developing biocompatible materials and advanced manufacturing technologies.
- Strategic Partnerships and Acquisitions: DSM can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. By collaborating with other companies and acquiring complementary businesses, DSM can accelerate its growth and strengthen its competitive position. This includes partnering with startups and research institutions to access cutting-edge technologies and expanding into new markets through strategic acquisitions. These collaborations can enhance DSM's innovation pipeline and market access.
- Digital Transformation and Data Analytics: DSM can leverage digital technologies and data analytics to improve its operational efficiency, enhance customer engagement, and drive innovation. By implementing digital solutions across its value chain, DSM can optimize its processes, reduce costs, and improve decision-making. This includes using data analytics to personalize customer interactions, optimize supply chain management, and accelerate research and development. Digital transformation can also enable DSM to develop new business models and revenue streams.
Opportunities
- Expansion in personalized nutrition and sustainable materials.
- Growth in biomedical materials for medical devices and implants.
- Strategic partnerships and acquisitions to expand market reach.
- Leveraging digital technologies and data analytics to improve efficiency.
Threats
- Intense competition from other specialty chemical and life science companies.
- Regulatory changes and environmental concerns.
- Economic downturns and market volatility.
- Disruptive technologies and changing consumer preferences.
Competitive Advantages
- Strong brand reputation and established market presence.
- Extensive portfolio of proprietary technologies and intellectual property.
- Diversified business model across multiple industries and geographies.
- Focus on innovation and sustainability, aligning with evolving market trends.
About KDSKF
Koninklijke DSM N.V., founded in 1902 and headquartered in Heerlen, Netherlands, is a science-based company focused on nutrition, health, and sustainable living. Originally established as the Dutch State Mines, DSM has evolved from a coal mining company into a global leader in specialty chemicals and life sciences. The company operates through three primary segments: Nutrition, Materials, and Innovation Center. The Nutrition segment offers a wide array of products, including animal nutrition and health solutions, human nutrition and health products, and specialty food enzymes. The Materials segment provides specialty plastics and Dyneema fiber solutions for various industries, including electronics, automotive, and personal protection. The Innovation Center focuses on biomedical materials and medical device technologies. DSM's global presence spans across Europe, North America, Latin America, Asia, and other international markets, serving diverse customer needs with innovative and sustainable solutions. With a workforce of 19,263 employees, DSM continues to invest in research and development to drive innovation and growth in its core business areas.
What They Do
- Develops and produces animal nutrition and health products, including vitamins and enzymes.
- Offers human nutrition and health products, such as vitamins, minerals, and nutritional lipids.
- Provides specialty plastics for the electrical, electronics, and automotive industries.
- Manufactures Dyneema, a high-strength fiber used in personal protection and sports apparel.
- Develops biomedical materials for medical devices and implants.
- Commercializes yeast technology for ethanol production.
- Offers premix, market-ready solutions, and personalized nutrition.
Business Model
- Develops and manufactures a wide range of products across nutrition, materials, and biomedical segments.
- Sells products to various industries, including animal feed, food and beverage, electronics, and healthcare.
- Generates revenue through product sales, licensing agreements, and service offerings.
- Invests in research and development to drive innovation and create new products and solutions.
Industry Context
Koninklijke DSM N.V. operates within the specialty chemicals industry, which is characterized by innovation, sustainability, and evolving consumer preferences. The market is driven by increasing demand for advanced materials, nutritional products, and healthcare solutions. DSM competes with companies like BOALF, BOALY, FCREY, HDELY, and INCZY, each vying for market share through differentiated products and services. The industry is also influenced by regulatory trends, environmental concerns, and technological advancements. DSM's focus on sustainable solutions and its diversified portfolio position it to capitalize on emerging opportunities in the market.
Key Customers
- Animal feed manufacturers seeking to improve animal health and nutrition.
- Food and beverage companies looking for specialty ingredients and solutions.
- Electronics and automotive manufacturers requiring high-performance plastics.
- Medical device companies needing biomedical materials for implants and devices.
- Consumers seeking nutritional supplements and health products.
Financials
Chart & Info
Koninklijke DSM N.V. (KDSKF) stock price: Price data unavailable
Latest News
-
DSM-Firmenich AG (KDSKF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 12, 2026
-
DSM-Firmenich AG (DSFIY) Shareholder/Analyst Call Transcript
seekingalpha.com · Feb 9, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KDSKF.
Price Targets
Wall Street price target analysis for KDSKF.
MoonshotScore
What does this score mean?
The MoonshotScore rates KDSKF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dimitri de Vreeze
Co-CEO
Dimitri de Vreeze serves as Co-CEO of DSM, bringing extensive experience in the chemical and materials industries. Prior to his current role, he held various leadership positions within DSM, including roles in marketing, sales, and operations. His career spans over two decades, during which he has demonstrated a strong track record of driving growth and innovation. He is known for his strategic vision and commitment to sustainability. His leadership is focused on driving DSM's transformation into a leading health, nutrition and bioscience company.
Track Record: Under Dimitri de Vreeze's leadership, DSM has focused on strengthening its position in nutrition, health, and sustainable living. Key achievements include strategic acquisitions and partnerships to expand the company's product portfolio and geographic reach. He has also overseen the implementation of sustainable practices across DSM's operations, contributing to the company's environmental goals. He played a key role in the strategic decision to merge with Firmenich.
KDSKF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Koninklijke DSM N.V. (KDSKF) may not meet the listing requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as exchange-listed companies. This tier is also known as the Grey Market. Investing in companies on the OTC Other tier carries higher risks due to the potential for less transparency and liquidity compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for lower liquidity and wider bid-ask spreads.
- Higher price volatility compared to exchange-listed stocks.
- Increased risk of fraud or manipulation due to less regulatory oversight.
- Dependence on the company's ability to meet future financial reporting requirements.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Determine the liquidity and trading volume of the stock.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established history as a science-based company.
- Global presence and operations in multiple countries.
- Diversified business model across nutrition, materials, and biomedical segments.
- Focus on innovation and sustainability.
- Presence of a CEO with a track record in the industry.
What Investors Ask About Koninklijke DSM N.V. (KDSKF)
What does Koninklijke DSM N.V. do?
Koninklijke DSM N.V. is a global science-based company operating in nutrition, health, and sustainable living. The company develops, manufactures, and sells a wide range of products, including animal nutrition and health products, human nutrition and health products, specialty plastics, and biomedical materials. DSM serves various industries, including animal feed, food and beverage, electronics, and healthcare, providing innovative solutions to meet evolving market needs. The company's focus on sustainability and innovation positions it as a key player in the specialty chemicals and life sciences sectors.
What do analysts say about KDSKF stock?
Analyst consensus on KDSKF stock is currently pending further AI analysis. Key valuation metrics to consider include the company's P/E ratio of 41.69, which suggests a premium valuation. Growth considerations include the company's expansion in personalized nutrition, sustainable materials, and biomedical materials. Investors should monitor the company's ability to maintain its profit margin of 5.7% and effectively manage its beta of 0.72 in a dynamic market environment. The dividend yield of 0.82% provides a modest income stream.
What are the main risks for KDSKF?
The main risks for KDSKF include intense competition from other specialty chemical and life science companies, regulatory changes and environmental concerns, economic downturns and market volatility, fluctuations in raw material prices, and dependence on research and development for future growth. The company's relatively low profit margin compared to some competitors and its high P/E ratio also pose potential risks. Investors should carefully consider these factors before investing in KDSKF stock. Additionally, the OTC market presents unique risks.
What are the key factors to evaluate for KDSKF?
Koninklijke DSM N.V. (KDSKF) currently holds an AI score of 41/100, indicating low score. Key strength: Diversified business model across nutrition, materials, and biomedical segments.. Primary risk to monitor: Potential: Intense competition from other specialty chemical and life science companies.. This is not financial advice.
How frequently does KDSKF data refresh on this page?
KDSKF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KDSKF's recent stock price performance?
Recent price movement in Koninklijke DSM N.V. (KDSKF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified business model across nutrition, materials, and biomedical segments.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KDSKF overvalued or undervalued right now?
Determining whether Koninklijke DSM N.V. (KDSKF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KDSKF?
Before investing in Koninklijke DSM N.V. (KDSKF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The OTC analysis is based on limited information available for KDSKF.
- AI analysis is pending for KDSKF, which may provide further insights.
- Financial data is based on the most recent available information.